LitAlert ~~ GeneLit.com

    • Contralateral Prophylactic Mastectomy: A Narrative Review of the Evidence and Acceptability.
    • Scheepens JCC, van ’t Veer L, Esserman L, Belkora J, Mukhtar RA.
    • Breast. 2021 Feb 10:S0960-9776(21)00017-5. doi: 10.1016/j.breast.2021.02.003. Epub ahead of print.
    • Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers.
    • Marcinkute R, Woodward ER, Gandhi A, Howell S, Crosbie EJ, Wissely J, Harvey J, Highton L, Murphy J, Holland C, Edmondson R, Clayton R, Barr L, Harkness EF, Howell A, Lalloo F, Evans G.
    • J Med Genet. 2021 Feb 10:jmedgenet-2020-107356. doi: 10.1136/jmedgenet-2020-107356. Epub ahead of print.
    • Update: variable implementation of the 2018 UKCGG/UKGTN guidelines for breast cancer gene panel tests offered by UK genetics services.
    • Wedderburn S, Archer S, Tischkowitz M, Hanson H, on behalf of UKCGG.
    • J Med Genet. 2021 Feb 10:jmedgenet-2020-107529. doi: 10.1136/jmedgenet-2020-107529. Epub ahead of print.
    • Germline mutational spectrum in Armenian breast cancer patients suspected of hereditary breast and ovarian cancer.
    • Moradian MM, Babikyan DT, Markarian S, Petrosyan JG, Avanesian N, Arutunyan T, Sarkisian TF.
    • Hum Genome Var. 2021 Feb 9;8(1):9. doi: 10.1038/s41439-021-00140-2.
    • Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis.
    • Baum J, Braicu EI, Hunsicker O, Vergote I, Concin N, Van Nieuwenhuysen E, Feldheiser A, Achimas-Cadariu P, Darb-Esfahani S, Berger A, Fetica B, Mahner S, Papadia A, Wölber L, Gasparri ML, Vanderstichele A, Benedetti Panici P, Mueller MD, Ruscito I, Woopen H, Sehouli J.
    • Int J Gynecol Cancer. 2021 Feb 9:ijgc-2020-002023. doi: 10.1136/ijgc-2020-002023. Epub ahead of print.
    • Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
    • Kurian AW, Ward KC, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Morrow M, Berek JS, Hofer TP, Katz SJ.
    • J Clin Oncol. 2021 Feb 9:JCO2002785. doi: 10.1200/JCO.20.02785. Epub ahead of print.
    • Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel.
    • Jiang W, Li L, Ke CF, Wang W, Xiao BY, Kong LH, Tang JH, Li Y, Wu XD, Hu Y, Guo WH, Wang SZ, Wan DS, Xu RH, Pan ZZ, Ding PR.
    • J Med Genet. 2021 Feb 9:jmedgenet-2020-107230. doi: 10.1136/jmedgenet-2020-107230. Epub ahead of print.
    • Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer.
    • Kwon JS.
    • J Gynecol Oncol. 2021 Feb 8:e33. doi: 10.3802/jgo.2021.32.e33. Epub ahead of print.

    Original research:

    Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer.

    • Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer.
    • Kato S.
    • Diagnostics (Basel). 2021 Feb 6;11(2):252. doi: 10.3390/diagnostics11020252.
    • Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.
    • Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK.
    • Gynecol Oncol. 2021 Feb 6:S0090-8258(20)34181-0. doi: 10.1016/j.ygyno.2020.12.010. Epub ahead of print.
    • Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore.
    • Tan DS, Chan JJ, Hettle R, Ghosh W, Viswambaram A, Yu CC.
    • J Gynecol Oncol. 2021 Jan 18:e27. doi: 10.3802/jgo.2021.32.e27. Epub ahead of print.